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Colorectal cancer primarily metastasizes to the liver
and globally kills over 600,000 people annually.
By functionally screening 661 microRNAs (miRNAs)
in parallel during liver colonization, we have identi-
fied miR-551a and miR-483 as robust endogenous
suppressors of liver colonization and metastasis.
These miRNAs convergently target creatine kinase,
brain-type (CKB), which phosphorylates themetabo-
lite creatine, to generate phosphocreatine. CKB is
released into the extracellular space by metastatic
cells encountering hepatic hypoxia and catalyzes
production of phosphocreatine, which is imported
through the SLC6A8 transporter and used to
generate ATP—fueling metastatic survival. Combi-
natorial therapeutic viral delivery of miR-551a and
miR-483-5p through single-dose adeno-associated
viral (AAV) delivery significantly suppressed colon
cancer metastasis, as did CKB inhibition with a
small-molecule inhibitor. Importantly, human liver
metastases express higher CKB and SLC6A8 levels
and reducedmiR-551a/miR-483 levels relative to pri-
mary tumors. We identify the extracellular space as
an important compartment for malignant energetic
catalysis and therapeutic targeting.INTRODUCTION
Colorectal cancer is the third leading cause of mortality in the
United States and a major cause of death globally (Davis and
Schlessinger, 2012; Jemal et al., 2011; Siegel et al., 2014). Death
from colorectal cancer is primarily due to themetastatic progres-
sion, with the liver being the organ of metastatic colonization in
over 70% of patients. To date, efforts aimed at increasing cure
rates after surgery have focused on combination chemotherapy
administration as a means of preventing metastasis. Such ther-
apy reduces metastatic relapse by roughly 7% (Meyerhardt and
Mayer, 2005). The high prevalence of this disease and the lack of
effective adjuvant therapeutics demand a greater understandingof the biology of its progression (Markowitz and Bertagnolli,
2009).
In recent years, posttranscriptional deregulation has emerged
as a key feature of metastatic cells. In particular, specific micro-
RNAs (miRNAs), which are small noncoding RNAs, have been
identified that are silenced or overexpressed and act to suppress
or promote metastatic progression by diverse cancer types (Lu-
jambio and Lowe, 2012; Ma et al., 2007; Pencheva and Tavazoie,
2013; Pencheva et al., 2012; Tavazoie et al., 2008). While the use
of these miRNAs as molecular probes for the identification of
metastasis regulators has proved fruitful, their therapeutic utility
has been limited given the inefficient delivery of miRNAs into
various metastatic tissues. Interestingly, the liver represents an
exception to this rule, because miRNAs tend to accumulate in
hepatic tissue and because vectors such as adeno-associated
viruses and nanoparticles have shown promising efficacy in
enhancing hepatic delivery in nonhuman primates and humans
(Kota et al., 2009; Mingozzi and High, 2011). Given this unique
feature of the liver aswell as the great need for targeted therapies
that can suppress liver metastatic colonization by colon cancer,
the identification of miRNAs that could suppress liver metastasis
would be of great clinical value.
By screening 661 human miRNAs in parallel for their ability to
suppress the colonization of the liver by multiple colon cancer
cell lines representing diverse mutational subtypes, we have
identified miR-551 and miR-483 as endogenous suppressors
of colon cancer metastasis. We find that these miRNAs both
target Creatine kinase Brain (CKB). Disseminated metastatic
cells release this enzyme into the extracellular space, where it
catalyzes the phosphorylation of the metabolite creatine by us-
ing extracellular ATP as the phosphate source. Phosphocreatine
is then imported into disseminated colorectal cancer cells where
its high-energy phosphate is used to generate intracellular ATP
that sustains the energetic requirements of colon cancer cells
encountering hepatic hypoxia, allowing them to survive this bar-
rier to metastatic progression. Therapeutic viral delivery of these
miRNAs to the liver and disseminated colon cancer cells via ad-
eno-associated viral delivery strongly suppresses metastatic
colonization by colon cancer cells. Moreover, small-molecule
therapeutic inhibition of CKB activity also suppresses metastatic
growth. Our findings delineate a druggable molecular network
that governs both the metabolic state and the metastatic pro-
gression capacity of disseminated colon cancer cells. MoreCell 160, 393–406, January 29, 2015 ª2015 Elsevier Inc. 393
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importantly, we implicate the extracellular space as a previously
unrecognized environment for malignant catalysis and identify
CKB as a secreted metabolic kinase that drives cancer
progression.
RESULTS
Endogenous miR-483-5p and miR-551a Suppress
Human Colorectal Cancer Metastasis
In vivo selection has been used by many investigators to identify
candidate genes that regulate metastatic progression of diverse
cancer types. This approach allows one to derive highlymetasta-
tic subpopulations with enhanced metastatic activity for a given
organ (Fidler, 1973). The comparison of transcriptomic profiles of
metastatic derivatives to the parental lines from which that they
were derived has revealed numerous candidate genes for func-
tional testing (Bruns et al., 1999; Kang et al., 2003; Minn et al.,
2005; Pencheva et al., 2012; Png et al., 2012; Tavazoie et al.,
2008). As a first step to identify the molecular regulators of liver
colonization by colon cancer cells, we performed in vivo selec-
tion on the LS-174T (K-Ras mutant) human colon cancer line
for enhanced liver colonization activity through iterative intra-he-
patic injection of cancer cells into immunodeficient mice fol-
lowed by surgical resection of liver colonies and dissociation of
cells. Independently derived third-generation liver colonizers
LS-LvM3a and LS-LvM3b displayed significantly enhanced
(>50-fold) capacity for liver colonization upon intrahepatic injec-
tion relative to their parental line (Figure 1A). Importantly, these
derivatives also displayed dramatically enhanced (>150-fold)
liver metastatic capacity upon portal circulation injection in
metastasis assays (Figure S1A available online)—revealing the
acquisition of liver colonization capacity to be sufficient for im-
parting enhanced liver metastasis activity. As an orthogonal
approach, we transduced a library of lentiviral particles, each en-
coding one of 661 human miRNAs, into two independent colon
cancer cell lines—the WiDR (K-Ras wild-type) and SW620 (K-
Ras mutant) human lines. These cancer populations, containing
cancer cells expressing each of 661 miRNAs, were then intrahe-
patically injected into mice to allow for selection of cells capable
of colonizing the liver. Genomic PCR amplification of lentiviral-
derivedmiRNA sequences andmiRNA profiling of miRNA insertsFigure 1. miR-483-5p and miR-551a Are Endogenous miRNAs that Sup
(A) Bioluminescence plot of liver colonization by 53 105 LS-Parental, LvM3a, and
21 after injection and livers extracted for ex vivo imaging and gross morphologica
normalized to signal on day 0.
(B) Schematic for the identification of miR-483-5p and miR-551a as suppressors
(C) Liver metastasis of mice injected with 5 3 105 LvM3b cells overexpressing e
(D) Liver metastasis in mice injected with 5 3 105 SW480 cells, whose endogeno
(E and F) Organotypic slice culture imaging of SW480 cells (n = 8) whose endogeno
labeled with cell-tracker green (control LNA) or cell-tracker red (miRNA-specific L
were performed to compensate for dye bias. Representative images at day 0 and
measured and normalized to start of experiment. Scale bar represents 50 mm.
(G) Bioluminescent metastatic signal from mice (n = 5) injected with 53 105 SW4
Images and measurements were taken 24 hr after tumor cells inoculation.
(H) Relative in vivo caspase activity of SW480 cells whose endogenous miR-483
a caspase-3/7-activated DEVD-luciferin and normalized with bioluminescent sig
one-sided Student’s t tests, or where appropriate, Mann-Whitney test for non-G
See also Figure S1 and Tables S1 and S2.allowed for the quantification of miRNA insert representation
(Figure 1B; Table S1). We identified miRNAs that displayed
reduced representation in the context of liver colonization in
both colon cancer cell-lines on the basis that overexpression
of these miRNAs suppressed liver colonization by colon cancer
cells. We next asked whether endogenous forms of these miR-
NAs exhibited silencing in highly metastatic derivatives relative
to isogenic poorly metastatic parental cells. Indeed, two of the
miRNAs, miR-483-5p and miR-551a, were found to be silenced
in highly metastatic LS-LVM3a and LS-LVM3b liver colonizers
relative to their parental line (Figure S1B; Table S2). Consistent
with a suppressive role for these miRNAs in liver colonization,
overexpression of miR-483-5p ormiR-551a robustly suppressed
metastatic colonization by LS-LvM3b cells introduced into the
portal circulation (Figures 1C and S1C), while inhibition of endog-
enous miR-483-5p or miR-551a in poorly metastatic parental
lines SW480 and LS-174T significantly enhanced liver metastatic
colonization (Figures 1D and S1D). The effects of these miRNAs
on metastatic progression were not secondary to modulation of
proliferative capacity because miR-551a inhibition did not affect
in vitro proliferation, while miR-483-5p inhibition minimally
increased proliferation (10%)—an order of magnitude less than
its effect on metastasis (Figure S1E). Importantly, overexpres-
sion of either miRNA did not suppress primary tumor growth
(Figure S1F).
To better investigate the mechanism(s) by which these miR-
NAs exert their anti-metastatic effects, we employed an in vitro
liver organotypic slice culture system to study early events dur-
ing liver metastasis subsequent to single-cell dissemination of
colon cancer cells in the liver microenvironment (Figure S1G).
Consistent with prior studies, which revealed a significant selec-
tion on cell survival during metastatic colonization (Gupta and
Massague´, 2006; Talmadge and Fidler, 2010), we noted that
highly metastatic LvM3b cells were significantly better at persist-
ing in the liver microenvironment than their poorly metastatic
parental line; consistent with a key role for intrahepatic persis-
tence in metastatic progression (Figure S1H). We examined
whether the enhanced capacity of metastatic cells to persist in
the hepatic microenvironment is regulated by miR-483-5p or
miR-551a. Indeed, overexpression of miR-483-5p and miR-
551a in LS-LvM3b cells suppressed (Figures S1I and S1J), whilepress Liver Metastasis
LvM3b cells after direct intrahepatic injection (n > 5). Mice were imaged at day
l examination. Photon flux ratio is the ratio of bioluminescence signal at day 21
of metastasis.
ither a control hairpin, miR-483-5p, or miR-551a (n > 5).
us miR-483-5p or miR-551a was inhibited (n > 5).
us miR-483-5p (E) or miR-551a (F) were inhibited by LNAs. Cells (53 105) were
NA) and introduced into the livers prior to slice culture. Dye-swap experiments
day 3 are shown. Total area of each cell population at indicated time points are
80 cells whose endogenous miR-483-5p or miR-551a activities were inhibited.
-5p or miR-551a was inhibited (n = 3). Caspase activity was monitored using
nal from regular luciferin. Error bars represent SEM; all p values are based on
aussian distribution. *p < 0.05; **p < 0.01; ***p < 0.001.
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inhibition of these miRNAs enhanced (Figures 1E and 1F) colon
cancer persistence in the hepatic microenvironment. In agree-
ment with our organotypic slice culture findings, we noted that
as early as 24 hr after injection of cells into the portal circulation,
cells whose endogenous miRNAs were inhibited out-competed
control cells (Figure 1G). As neither of thesemiRNAs significantly
affected proliferation, we asked if they elicited their effects by
suppressing cancer cell survival during metastatic progression.
To quantify cell death in vivo, we utilized a bioluminescence-
based luciferin reporter of caspase-3/7 activity (Hickson et al.,
2010). MiRNA inhibition significantly reduced in vivo caspase
activity in colon cancer cells during the early phase of hepatic
colonization (Figure 1H), revealing cancer survival to be the
phenotype suppressed by these miRNAs. These in vivo findings
provide corroboration and a mechanistic basis for the organo-
typic slice culture observations. Our findings reveal miR-483
and miR-551a to suppress liver metastatic colonization through
suppression of metastatic cell survival in the liver—a phenotype
exhibited by highly metastatic colon cancer cells.
miR-483-5p and miR-551a Suppress Colorectal Cancer
Cell Survival and Metastasis in the Liver through
Targeting of CKB
We next sought to identify the downstream effectors of these
miRNAs. Through transcriptomic profiling, we identified tran-
scripts that were downregulated by overexpression of each
miRNA and that contained 30-UTR or coding-sequence elements
complementary to themiRNAs. Interestingly, CKBwas identified
as a putative target of both miRNAs, suggesting that these miR-
NAs, which exhibit common in vivo and organotypic phenotypes,
mightmediate their effects through a common target gene (Table
S3). Importantly, endogenous miR-483 and miR-551a were
found to suppress CKB protein levels (Figure 2A). Quantitative
RT-PCR validation also revealed suppression or upregulation
of CKB transcript levels upon overexpression or inhibition of
the miRNAs, respectively (Figures S2A and S2B). Mutagenesis
and luciferase-based reporter assays revealed miR-483 to
directly target the 30UTR andmiR-551a to directly target the cod-
ing region of CKB (Figures S2C and S2D). Overexpression of
CKB in poorly metastatic SW480 cells was sufficient to signifi-
cantly enhance liver metastasis (>3-fold; Figure 2B), while CKB
knockdown in metastatic LS-LvM3b cells and SW480 cells,
through the use of two independent hairpins for each line,
robustly suppressed liver metastatic colonization (>5-fold; Fig-
ures 2C and S2E). Importantly, metastases that grew out in
knockdown experiments had ‘‘escaped’’ small hairpin RNA
(shRNA) knockdown and displayed restored CKB expression
(Figure S2F). Consistent with the effects of its regulatory miR-
NAs, CKB overexpression was sufficient to significantly enhance
the ability of colon cancer cells to persist in the liver micro-
environment and enhanced their representation in the liver
(Figure 2D), while CKB knockdown substantially reduced intra-
hepatic persistence (Figure 2E). Consistent with this, CKB over-
expression reduced (Figure 2F), while CKB knockdown signifi-
cantly enhanced (Figure 2G), in vivo caspase-3/7 activity in colon
cancer cells during the initial phase of hepatic colonization. To
investigate whether CKB acts directly downstream of miR-483-
5p and miR-551a, we performed gain-of-function, loss-of-func-396 Cell 160, 393–406, January 29, 2015 ª2015 Elsevier Inc.tion, and epistasis studies. Knockdown of CKB in cells inhibited
formiR-483-5p ormiR-551a prevented the enhancedmetastasis
effect seen with miR-483-5p or miR-551a silencing (Figure 2H).
Conversely overexpression of CKB was sufficient to rescue the
suppressed liver metastatic phenotypes of cells overexpressing
miR-483-5p or miR-551a (Figure S2G). The results of the above
mutational, gain-of-function, loss-of-function, and epistasis ana-
lyses reveal CKB to be a direct target of miR-483-5p and miR-
551a, to act as a downstream effector of these miRNAs in the
regulation of colon cancer metastatic progression, and be a
promoter of colon cancer survival during hepatic metastatic
colonization.
CKB Promotes Colorectal Cancer Cell Survival during
Acute Intrahepatic Hypoxia through Modulation of the
Phosphocreatine/ATP Shuttle
CKB is known to regulate the reservoir of rapidly mobilized high-
energy phosphates in tissues such as the brain by catalyzing
the transfer of a high-energy phosphate group from ATP to the
metabolite creatine, yielding phosphocreatine (Wyss and
Kaddurah-Daouk, 2000). Recent studies have implicated the
involvement of metabolic pathways in tumorigenesis and cancer
progression (Cairns et al., 2011; Christofk et al., 2008; Dang
et al., 2009; Kaelin and McKnight, 2013). The maintenance of
intracellular ATP levels is also critical for cancer cell survival un-
der metabolic stress (Jeon et al., 2012). Highly metabolic cells
maintain phosphocreatine stores in order to buffer against low
ATP states, because phosphocreatine’s high-energy phosphate
can be transferred to ADP to generate ATP (Wallimann et al.,
1992; Wyss and Kaddurah-Daouk, 2000). Consistent with this,
overexpression and knockdown of CKB in colon cancer cells
increased and decreased, respectively, intracellular phospho-
creatine levels (Figure 3A) and CKB depletion resulted in
decreased ATP levels that could be rescued by phosphocreatine
supplementation (Figure 3B). Consistent with our findings that
miR-483 and miR-551a regulate CKB expression, modulation
of either of these miRNAs also modulated intracellular phospho-
creatine (Figures S3A and S3B) and ATP levels (Figures S3C and
S3D).What purpose could CKB-generated phosphocreatine and
ATP play during colon cancer metastatic progression? The liver
microenvironment is known to contain hypoxic regions, with
metabolically active hepatocytes at the periportal region display-
ing high rates of oxygen consumption and hepatocytes at the
perivenous region actively undergoing glycolysis (Arteel et al.,
1995; Jungermann and Kietzmann, 2000). Additionally, colon
cancer cells metastasize to the liver via the portal circulation,
which is relatively hypoxemic. We hypothesized that colorectal
cancer cells experience acute hypoxia and intense competition
for glycolytic substrates during initial dissemination to the liver
and could be poorly adapted to the liver microenvironment prior
to HIF-activated responses (Semenza, 2011). ATP generated
from rapid utilization of intracellular phosphocreatine reservoirs
might enable colon cancer cells to survive acute hepatic hypox-
ia. To determine if colon cancer cells experience hypoxia during
early metastatic colonization, we utilized a Hif-1 alpha transcrip-
tional luciferase-reporter (HRE-Luc) as an in vivo sensor and
reporter of cellular hypoxia (Figure S3E) and observed that
colon cancer cells experience hypoxia early after hepatic
sh
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Figure 2. miR-483-5p and miR-551a Suppress Colorectal Cancer Cells Survival and Metastasis in the Liver through Regulation of CKB
(A) Expression of CKB in SW480 cells whose endogenous miR-483-5p or miR-551a was inhibited with LNAs.
(B) Liver metastasis inmice injected intrasplenically with 53 105 control SW480 cells or CKB overexpressing SW480 cells (n = 5). Mice were euthanized at 28 days
after injection.
(C) Liver metastasis in mice injected intrasplenically with 5 3 105 LvM3b expressing a control hairpin or two independent shRNA hairpins targeting CKB (n = 6).
Mice were euthanized 21 days after injection.
(D) Survival of control SW480 and CKB overexpressing SW480 cells in organotypic liver slices (n = 8).
(E) Survival of LvM3b cells expressing a control hairpin or hairpin targeting CKB in organotypic slice cultures (n = 8). Representative images at day 0 and day 2 are
shown. Scale bar represents 50 mm.
(F) Relative in vivo caspase activity of control or CKB overexpressing SW480 cells. Caspase activity was measured on days 1, 4, and 7 after injection (n = 3).
(G) Relative in vivo caspase-3 activity of SW480 cells expressing a control shRNA or shRNA targeting CKB. Caspase activity was measured on days 1, 4, and 7
after injection (n = 3).
(H) Liver metastasis in mice injected with 5 3 105 SW480 cells whose endogenous miR-483-5p or miR-551a was inhibited by LNA, with and without CKB
knockdown. Error bars represent SEM; all p values are based on one-sided Student’s t tests, or where appropriate, Mann-Whitney test for non-Gaussian dis-
tribution. *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S2 and Table S4.
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AC
E
F
D
B Figure 3. CKB Modulates Colorectal Cancer Cell Survival during
Acute Intrahepatic Hypoxia through Modulation of the Phospho-
creatine/ATP Shuttle
(A) Relative intracellular phosphocreatine levels in SW480 cells overexpressing
CKB or depleted for CKB (n = 5).
(B) Relative intracellular ATP levels in LvM3b cells depleted for CKB, with and
without exogenous 10 mm phosphocreatine supplementation (n = 5).
(C) In vivo caspase activity of control and CKB knockdown SW480 cells
experiencing hypoxia within the livers of mice (n = 3).
(D) Survival of colorectal cancer cells in hypoxia in vitro with and without CKB
knockdown and 10 mm phosphocreatine supplementation (n = 3).
(E) Liver metastasis by CKB depleted LvM3b cells with and without overnight
preincubation with 10 mM phosphocreatine. Cells (5 3 105) were then inocu-
lated into the liver of mice through intrasplenic injection.
(F) Liver metastasis in mice injected with 53 105 LvM3b cells with and without
pretreatment with 10 mM cyclocreatine for 48 hr. Error bars represent SEM; all
p values are based on one-sided Student’s t tests, or where appropriate,
Mann-Whitney test for non-Gaussian distribution. *p < 0.05; **p < 0.01;
***p < 0.001.
See also Figure S3.
398 Cell 160, 393–406, January 29, 2015 ª2015 Elsevier Inc.dissemination (Figure S3F). We found that CKB depletion
increased caspase-mediated cell death in HRE-Luc expressing
cells experiencing hypoxia in vivo (Figure 3C). Conversely, inhi-
bition of either miR-483-5p or miR-551a protected HRE-Luc
expressing cells experiencing hypoxia in vivo (Figure S3G).
Consistent with a role for CKB and phosphocreatine in promot-
ing cancer-cell survival during hypoxia, cells depleted of CKB
through RNAi displayed reduced survival while experiencing
hypoxia in vitro—an effect that was abrogated upon phospho-
creatine supplementation (Figure 3D). In agreement with our
in vitro findings, preincubation of colon cancer cells depleted
of CKB with phosphocreatine enhanced their ability to metasta-
size to the liver (Figure 3E). Conversely, liver metastasis was
inhibited when we preincubated colon cancer cells with cyclo-
creatine (Lillie et al., 1993), an inhibitor of CKB that depletes
phosphocreatine levels (Figure 3F). Our findings suggest that he-
patic hypoxia poses a barrier for colon cancer cells during early
metastatic colonization and that cells endure this phase through
the generation of ATP from phosphocreatine reserves. Indeed,
the ability of phosphocreatine preloading to enhance metastasis
in vivo supports the importance of the acute initial hypoxic barrier
and energetic demands in shaping metastatic colonization by
cancer cells as they enter the liver microenvironment.
CKB Is Secreted by Colorectal Cancer Cells and
Promotes Malignant Conversion of Extracellular ATP
and Creatine to Phosphocreatine
While considering CKB’s role in the setting of the hypoxic hepat-
ic microenvironment that colorectal cancer cells arrive into as
they disseminate from the gut to the liver, we faced a conun-
drum: how can colon cancer cells arriving and residing in a hyp-
oxic hepatic microenvironment replenish phosphocreatine if
they are depleted of ATP, especially during the acute phase,
prior to any hypoxia-response (Bertout et al., 2008; Semenza,
2013; Wheaton and Chandel, 2011)? Earlier clinical studies
have described the detection of CKB proteins and CKB activity
in the sera of patients with various forms of malignancies and
physiological insults (Huddleston et al., 2005; Rubery et al.,
1982; Wyss and Kaddurah-Daouk, 2000). The presence of
extracellular ATP in the microenvironment of macrometastases
was also reported (Pellegatti et al., 2008; Stagg and Smyth,
2010). Interestingly, the liver is the main synthetic organ for cre-
atine synthesis in the body. We hypothesized that colorectal
cancer cells may release CKB into the extracellular space, which
can then convert extracellular ATP and liver-produced creatine
into phosphocreatine that is then taken up by cancer cells,
thereby exerting a protective effect on hypoxic colorectal cancer
cells prior to their adaptation to the hypoxic liver microenviron-
ment. We thus investigated the possibility of metastatic colo-
rectal cancer cells releasing CKB extracellularly. Indeed, extra-
cellular CKB was released from metastatic LvM3b cells, but
not LvM3b cells expressing a CKB targeting shRNA (Figure 4A).
To determine if extracellular CKB was released from live or dying
cells, we expressed CKB tagged with a FLAG-epitope through
a linker containing a caspase-3/7 recognition DEVD motif.
Caspase activation in apoptotic cells would result in caspase
recognition and cleavage of the DEVD motif between the
FLAG-epitope tag and CKB, causing loss of the FLAG-epitope
from the expressed CKB (Figure 4B). We observed that extra-
cellular CKB was released primarily by live cells, as the FLAG-
epitope was not lost (Figure 4C). As generation of extracellular
phosphocreatine requires exogenous ATP and creatine, we
confirmed the presence of extracellular ATP in the microenvi-
ronment of incipient micrometastases using a plasma mem-
brane-anchored luciferase reporter for detecting extracellular
ATP (pME-Luciferase; Figure 4D) (Pellegatti et al., 2005). If the
prometastatic effects of CKB result from utilization of extracel-
lular ATP as a substrate, then depleting extracellular ATP should
suppress the prometastatic activity of CKB. Indeed, expressing
CD39, a plasma membrane anchored ATP hydrolase in SW480
cells significantly precluded the ability of CKB overexpression
to promote metastasis without affecting CKB levels (Figure 4E).
Consistent with CKB consumption of extracellular ATP, cells
overexpressing CKB or cells whose endogenous miR-483-5p
or miR-551a were inhibited displayed significantly lower extra-
cellular ATP levels in vivo relative to the control cells (Figures
4F and S4A). Conversely, the microenvironment surrounding
CKB knockdown cells displayed higher extracellular ATP levels
(Figure S4B). If extracellular CKB catalysis can enhance metas-
tasis, we reasoned that supplying the product of CKB-mediated
catalysis, phosphocreatine, in the extracellular space should
rescue the effect of CKB loss-of-function. In order to test this,
we implanted a mini-osmotic pump that continuously released
phosphocreatine into the peritoneal cavity of immunodeficient
mice, which is eventually drained into the portal circulation.
Remarkably, exogenous phosphocreatine was sufficient to
significantly enhance metastasis (>10-fold) by CKB-depleted
cells in vivo (Figure 4G). We next used a Boyden chamber cocul-
ture system to determine if colorectal cancer cells overexpress-
ing CKB could promote the survival of CKB knockdown cells un-
der hypoxia (Figure 4H). CKB overexpressing cells were indeed
able to compensate for the survival of CKB knockdown cells
across the trans-well, while addition of a CKB-activity neutral-
izing antibody abrogated this effect (Figure 4I). We extended
our findings to an in vivo system using colorectal cancer cells
depleted of intracellular CKB but expressing a secreted form of
CKB fused to the IgK secretory signal sequence. Remarkably,overexpressing secreted CKB was sufficient to enhance colo-
rectal cancer metastasis (Figure 4J). We further examined the
levels of serum CKB in mice injected with CKB knockdown cells.
Interestingly, we found that mice with escaped tumors invariably
had increased serum CKB levels (Figure S4C).
The Creatine Transporter SLC6a8 Modulates
CKB-Mediated Colorectal Cancer Metastasis
Having implicated exogenous creatine/phosphocreatine meta-
bolism in colorectal cancer metastasis, we next investigated
the regulation of creatine/phosphocreatine metabolism in colon
cancer metastatic progression. Depletion of guanidinoacetate
methyltransferase (GAMT), the enzyme required for the final
step of creatine synthesis, in colon cancer cells did not affect
metastasis (Figure S5A), consistent with a model wherein extra-
cellular (the liver is the primary site of creatine biosynthesis)
rather than intracellular creatine drives colorectal cancer metas-
tasis. Next, we asked if SLC6a8, a transporter of creatine com-
pounds (Salomons et al., 2001) modulates phosphocreatine
levels in colon cancer cells. Indeed, SLC6a8 knockdown re-
duced intracellular phosphocreatine and ATP levels (Figure 5A).
If extracellular phosphocreatine uptake promotes metastasis,
such impairment in phosphocreatine levels should reduce
metastasis. Indeed, multiple colon cancer cell lines depleted of
SLC6a8 displayed substantially reduced (10- to 100-fold) meta-
static activity (Figures 5B and S5B), whereas metastatic tumors
that eventually grew out from SLC6a8 knockdown cells were es-
capers and displayed restored SLC6a8 expression (Figure S5C).
Importantly SLC6a8 knockdown, which depleted cellular uptake
of extracellular phosphocreatine, also abrogated the effect
of CKB overexpression on colorectal cancer metastasis (Fig-
ure 5C), revealing extracellular phosphocreatine uptake to be
downstream of CKB catalysis. Additionally, depleting SLC6a8
in CKB knockdown cells abrogated the protective effect of phos-
phocreatine during hypoxic stress (Figure 5D). Finally exoge-
nously added phosphocreatine was not able to promote liver
metastasis by SLC6a8 knockdown cells (Figure S5D). These
findings reveal SLC6a8 to be downstream of CKB and phospho-
creatine and to mediate their metastasis promoting effects.
miR-483-5p, miR-551a, CKB, and SLC6a8 Associate
with Human Progression Stage
We next analyzed the expression levels of miR-483 and miR-
551a in a set of 66 surgically resected human primary colon
cancer and liver metastases from MSKCC. Consistent with a
metastasis-suppressive role for these miRNAs during cancer
progression, miR-483 and miR-551a both independently dis-
played significantly reduced expression levels in human liverme-
tastases relative to primary colon cancers (Figures 6A and 6B;
p = 0.02 for miR-483 and p = 0.001 for miR-551a; N = 66).
CKB (Figure 6C; p = 0.05, N = 233) and SLC6a8 (Figure 6D;
p < 0.001, N = 233) expression levels were significantly higher
in liver metastases relative to primary tumors in an independent
publicly available gene expression data set, suggesting a selec-
tion for enhanced expression of CKB and SLC6a8 during
progression. We also constructed a tissue microarray from a
collection of primary colorectal tumors and liver metastases
that were surgically resected from patients at Weill-CornellCell 160, 393–406, January 29, 2015 ª2015 Elsevier Inc. 399
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B C Figure 4. CKB Is Secreted by Colorectal Can-
cer Cells and Promotes Malignant Conversion
of Extracellular ATP and Liver Creatine to
Phosphocreatine to Enhance Metastasis
(A) Extracellular and intracellular CKBprotein levels in
control and LvM3b cells depleted of CKB through
RNAi.
(B) FLAG-tagged CKBwith a caspase 3/7 recognition
site linker. The FLAG-DEVD-CKB has a FLAG-tag
linked to the N terminus of CKB by a linker containing
a caspase 3/7 recognition motif (DEVD-amino se-
quence). Caspase activation in apoptotic cells will
result in cleavage of linker and release of FLAG-tag.
(C) Western blot of FLAG-DEVD-CKB overex-
pressing cells demonstrate release of CKB by non-
apoptotic cells into the extracellular space.
(D) Bioluminescent imaging of immunodeficient mice
injected with SW480 cells expressing pME-Luc for
detection of extracellular ATP (n = 5).
(E) Liver metastasis by 5 3 105 SW480 cells over-
expressing CKB with concomitant overexpression of
CD39.
(F) Relative extracellular ATP levels in CKB over-
expressing cells. Control and CKB overexpressing
pME-Luc SW480 cells were injected into mice (n = 5).
(G) Liver metastasis by CKB-depleted LvM3b cells in
mice implanted with an osmotic pump releasing
phosphocreatine into the portal circulation.
(H) Scheme for coculture experiment. CKB-knock-
down (5 3 104) cells were cultured on the bottom of
24-well plates, while control or CKB-overexpressing
cells were plated onto Boyden chambers above
CKB-knockdown cells with pores for exchange of
metabolites and proteins. Cells at the bottom of the
well were counted after 4 days in hypoxia.
(I) Relative survival of CKB-knockdown cells in 1%
oxygen when cocultured with control, CKB-over-
expressing cells or with CKB-overexpressing cells in
the presence of a neutralizing antibody (n = 4).
(J) Livermetastasis by endogenous CKB-knockdown
SW480 cells overexpressing a secreted form of CKB.
Error bars represent SEM; all p values are based on
one-sided Student’s t tests, or where appropriate,
Mann-Whitney test for non-Gaussian distribution.
*p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S4.
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Figure 5. SLC6a8 Modulates CKB-Mediated Colon Cancer Metastasis through Modulation of Intracellular Phosphocreatine Levels
(A) Relative intracellular phosphocreatine and ATP levels in LvM3b cells expressing a control shRNA or shRNA targeting SLC6a8 (n = 4).
(B) Liver metastasis by 5 3 105 LvM3b cells expressing two independent short hairpins targeting SLC6a8 (n = 5).
(C) Liver metastasis by SW480 cells overexpressing CKB with and without SLC6a8 depletion (n > 4).
(D) In vitro survival of LvM3b cells depleted of CKB, SLC6a8 with and without phosphocreatine supplementation in hypoxia (n = 3). Error bars represent SEM; all p
values are based on one-sided Student’s t tests, or where appropriate, Mann-Whitney test for non-Gaussian distribution. *p < 0.05; **p < 0.001; ***p < 0.0001.
See also Figure S5 and Table S4.Medical Center and immunohistochemically stained for CKB and
SLC6a8 expression. CKB (Figure 6E, p < 0.05, N = 92) and
SLC6a8 (Figure 6F, p < 0.001, N = 88) protein expression levels
were found to be elevated in liver metastases relative to primary
tumors of patients. These findings are consistent with, and sug-
gest the pathophysiological basis for, previous studies revealing
elevated expression levels of CKB in advanced stage cancer
(Wallimann and Hemmer, 1994) and reveal significant associa-
tion between the components of this multi-miRNA network and
colon cancer progression.
miR-483-5p, miR-551a, and CKB Modulation Provides
Clinical Benefit
We sought to investigate the therapeutic potential of targeting
this clinically relevant miRNA regulatory network. We first tested
the ability of adeno-associated virus to transduce colon cancer
cells in vitro and detected viral genomic DNA (gDNA) in colon
cancer cells even with low multiplicity of infection (Figure S6A).
Injection of mice bearing macroscopic hepatic metastases withadeno-associated virus revealed that adeno-associated virus
was able to infect colon cancer metastases in vivo (Figure S6B).
We next injectedmicewith 53 105 highly metastatic LvM3b cells
and 24 hr later administered a single intravenous dose of adeno-
viral-associated virus (AAV) encodingmiR-483-5p andmiR-551a
from a single transcript. Surprisingly, a single therapeutic dose of
AAV delivering both miRNAs dramatically and significantly
reduced metastatic colonization (>5-fold; Figure 6G). Therapeu-
tic efficacy was also seen in mice injected with SW480 cells (Fig-
ure 6H). Importantly, this treatment did not cause any adverse
phenotypic outcomes or pathological abnormalities in mice.
Moreover, autopsied mice treated with this AAV therapy did
not harbor spontaneous tumors. Even mice injected with
BEAS-2B immortalized lung epithelial cells that are prone to
oncogenic transformation did not develop tumors (Figure S6C).
We next investigated the therapeutic potential of targeting this
metabolic network by determining the impact of small-molecule
inhibition of CKB on colon cancer metastasis using cyclocrea-
tine. Therapeutic treatment of mice with cyclocreatine afterCell 160, 393–406, January 29, 2015 ª2015 Elsevier Inc. 401
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Figure 6. miR-483-5p, miR-551a, CKB, and SLC6a8 Are Clinically Relevant in Independent Cohorts of Patients and Can Be Therapeutically
Targeted
(A and B) miR-483-5p and miR-551a levels in 36 primary colorectal adenocarcinomas and 30 liver metastases were quantified by quantitative real-time PCR.
(C and D) CKB and SLC6a8 expression from a public microarray data set (GSE41258) comparing primary tumors and liver metastases (N = 233).
(legend continued on next page)
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Figure 7. Model for the miR-483-5p, miR-551a, CKB, and SLC6a8
Axis
Disseminated colon cancer cells arrive in the liver microenvironment through
the hypoxemic portal circulation. Within the liver microenvironment, they
experience hypoxic stress and ATP depletion. Cells that upregulate CKB
through loss of miRNAs, release CKB into the extracellular matrix where it
converts available creatine and ATP into phosphocreatine that is then taken up
by the cell to fuel metastatic survival and subsequent organ colonization.
Colon cancer cells with higher levels of CKB also build up a larger pool of
intracellular phosphocreatine that acts as a buffer against energetic stress.colorectal cancer cell inoculation also significantly reduced met-
astatic colonization, demonstrating proof-of-principle for target-
ing this kinase as a means of metastasis suppression (Figure 6I).
Given that the liver is a common site of metastasis for other
gastrointestinal cancers such as pancreatic cancer, we sought
to determine if knockdown of components in this pathway could
also inhibit metastasis by pancreatic cancer cells. Knockdown of
CKB and SLC6a8 in PANC1 cells (a KRAS mutant human
pancreatic line) with multiple shRNAs, strongly suppressed their
ability to metastasize (Figures 6J and S6G >10-fold). This finding
suggests that CKB and SLC6a8, and their associated metabolic
pathway, may more broadly govern liver metastasis by other
gastrointestinal cancers.
DISCUSSION
Colorectal cancer is diagnosed in over a million patients a year
globally, with the majority of advanced stage patients (over
600,000) experiencing liver metastatic progression (Jemal
et al., 2011). Using a systematic approach, we have identified
twomiRNAs that act as suppressors of liver metastatic coloniza-
tion by colon cancer cells. MiR-483-5p had been recently re-
ported to be oncogenic in lung adenocarcinoma by enhancing
invasion and progression and tumor growth in IGF2-dependent
sarcoma (Song et al., 2014), while miR-551a has been recently(E) CKB expression in primary tumors compared to liver metastases examined th
represents 50 mm.
(F) SLC6a8 expression in primary tumors compared to liver metastases examined
(N = 88). Scale bar represents 50 mm.
(G) Liver metastasis in mice injected with 5 3 105 LvM3b cells and treated with a
injection cells (n = 6).
(H) Liver metastasis in mice injected with 5 3 105 SW480 cells and treated with a
injection cells (n = 4).
(I) Liver metastasis in mice injected with 5 3 105 LvM3b cells and treated with cy
(J) Liver metastasis by pancreatic cancer cells, PANC1, with knockdown of CKB
values are based on one-sided Student’s t tests, or where appropriate, Mann-W
See also Tables S4 and S5.implicated in suppressing gastric cancer (Li et al., 2012b). Given
that miRNAs are widely known to act in a context-specific
manner, we had experimentally validated the role of these miR-
NAs in suppressing liver metastasis by colon cancer cells andwe
find that these miRNAs suppress a metabolic axis that drives
liver colonization by convergent targeting of CKB—a key gene
that allows colon cancer cells to expand their phosphocreatine
reserves during periods of positive cellular energy balance
(Wyss and Kaddurah-Daouk, 2000). Moreover, enhanced phos-
phocreatine reserves, which can fuel ATP generation, provide
great utility during periods of intense energetic requirement
such as during metastatic colonization of the liver microenviron-
ment—a hypoxic microenvironment that also contains perive-
nous hepatocytes that compete with cancer cells for glycolytic
substrates (Jungermann and Kietzmann, 1996). We find that co-
lon cancer cells, which enter the liver via the hypoxemic portal
circulation, undergo substantial cell death. Cells capable of
generating sufficient phosphocreatine reserves are better able
to survive the initial phase of hypoxic hepatic colonization. Colon
cancer cells that survive the initial selective pressure of hypoxic
hepatic dissemination can then activate pathways involved in
energy homeostasis and generation (DeBerardinis et al., 2008;
Hardie et al., 2012; Inoki et al., 2012; Jeon et al., 2012; Kaelin
and McKnight, 2013; Semenza, 2011) and harness additional
prometastatic programs for successful competition and further
colonization of the liver (Chiang and Massague´, 2008).
As incipient metastatic cells are dependent on CKB-mediated
intracellular phosphocreatine generation, which arises frommiR-
483-5p/miR-551a silencing and CKB overexpression, a selec-
tion for subpopulations that exhibit silencing of these miRNAs
and consequent induction of CKBwould occur. We demonstrate
that cells, which overexpress themetabolic kinase CKB, are able
to survive and progress within the hepatic parenchyma. How-
ever, in the context of energetic stress and ATP limitation, a
paradoxical situation would arise wherein intracellular phospho-
creatine generation from ATP would comprise a futile cycle.
Interestingly, we find that colon cancer cells secrete CKB into
the extracellular space, where it catalyzes the ATP-dependent
phosphorylation of creatine—yielding phosphocreatine (Fig-
ure 7). Extracellular phosphocreatine had been shown to be pro-
tective against hypoxic, ischemic, and other energetic insults in
neurons and myocardium, with increased phosphocreatine up-
take observed in ischemic myocardium (Brustovetsky et al.,
2001; Li et al., 2012a; Sharov et al., 1987). Our findings suggest
that colon cancer cells can actually generate extracellular phos-
phocreatine and import it as a means of enhancing energyrough immunohistochemical staining of a tissue microarray (N = 92). Scale bar
through immunohistochemical staining of above mentioned tissue microarray
single dose of AAV doubly expressing miR-483-5p and miR-551a 1 day after
single dose of AAV doubly expressing miR-483-5p and miR-551a 1 day after
clocreatine daily for 2 weeks (n > 15).
with two independent shRNA hairpins (n = 5). Error bars represent SEM; all p
hitney test for non-Gaussian distribution. *p < 0.05; **p < 0.01; ***p < 0.001.
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stores. Interestingly, we find that colon cancer cells have devel-
oped a remarkable adaptive mechanism—secretion of CKB—
that enables them to catalytically enhance extracellular phos-
phocreatine levels from exogenous precursors. The ‘‘harvest-
ing’’ of extracellular metabolites through secretion of CKB by
colon cancer cells thus represents a powerful mechanism for
survival when malignant cells are highly vulnerable.
While our findings reveal an important prometastatic role for
extracellular CKB, we do not rule out the possibility that intracel-
lular CKB could also play a role in cancer progression. One po-
tential intracellular role for CKB might occur during contexts
when cancer cells have adequate levels of ATP, such as during
primary tumor growth in the colonic epithelium, or subsequent
to metastatic tumor expansion and recruitment of functional
blood vessels, which could provide adequate oxygenation and
glucose for fueling ATP generation. In such contexts, intracel-
lular CKB could allow cancer cells to expand their intracellular
buffer of phosphocreatine to be drawn upon during subsequent
periods of reduced nutrients. While we have identified one
pathway that subserves cancer progression, it is possible that
malignant cells conduct other metabolic reactions in the extra-
cellular space that could allow for the extraction of extracellular
energy and substrates, or the degradation of toxic metabolic
wastes.
Our findings from human primary and metastatic tissue spec-
imens support our model (Figure 7), revealing enhanced
expression of CKB and reduced expression of its repressive
miRNAs in liver metastases—consistent with a selection for
cells with molecular activation of this pathway in the hepatic pa-
renchyma. While our findings have revealed a key pathway that
governs colon cancer metastatic colonization of the liver, the
predominant site of metastasis by colorectal cancer, and sug-
gest that the in vivo-selected metastatic sublines we have
derived display the same organotropism for the liver that the
majority of human colorectal cancers display, we do not
know if this pathway also regulates the colonization of other or-
gans such as the lungs by these cells. We speculate that part of
this organotropism may arise from the production of creatine
by the liver—the primary organ for creatine biosynthesis. Our
findings that CKB and SLC6a8 depletion suppress pancreatic
cancer metastasis highlight the possibility that additional
gastrointestinal cancer types, which exhibit tropism for the liver,
may also utilize this pathway and as such, may be also vulner-
able to CKB inhibition therapy.
While the promise of miRNA therapeutics has been great, its
actual clinical implementation has been more limited given inad-
equate stability and delivery of small RNA therapeutics to target
tissues. The liver, however, is an exceptional organ in this
respect, because miRNAs and RNAi molecules accumulate to
higher degrees in the hepatic parenchyma relative to other or-
gans and we have demonstrated adeno-associated virus to be
efficient in infecting colon cancer metastases. Additionally, ad-
eno-associated approaches of gene delivery have demonstrated
proof-of-concept in human trials (Nathwani et al., 2011). Given
these features of the liver, our identification of metastasis sup-
pressor miRNAs in colorectal cancer and our proof-of-principle
demonstration of their therapeutic activity have important clinical
implications because both nanoparticle-mediated and adeno-404 Cell 160, 393–406, January 29, 2015 ª2015 Elsevier Inc.associated viral delivery of these metastasis suppressors could
be viable paths clinically. A more conventional path toward tar-
geting this pathway could be the development of highly potent
inhibitors of CKB that would act in a similar manner as cyclocrea-
tine, given that highly specific kinase inhibitors can be designed
(Dar and Shokat, 2011; Davis and Schlessinger, 2012). Impor-
tantly, such inhibitors do not have to be cell-permeable, because
they would be targeting extracellular CKB. This could substan-
tially increase the therapeutic index of such compounds. The
poor overall efficacy of the current standard-of-care chemo-
therapy regimen FOLFOX in reducing metastatic relapse rates
in high-risk patients necessitates the development and testing
of such targeted therapeutic approaches in this prevalent
disease.
EXPERIMENTAL PROCEDURES
Animal Studies
All animal work was conducted in accordance with a protocol approved by
the Institutional Animal Care and Use Committee (IACUC) at The Rockefeller
University. Age-matched male NOD-SCID mice (5- to 6-week-old) were
used for organotypic slice culture, intrahepatic colonization, and liver metas-
tasis assays involving LS174T, SW620, WiDR, LvM3a, and LvM3b cell-lines.
Age-matched male NOD/SCID gamma male mice (5- to 6-week-old) were
used for liver metastasis assays for the SW480 and PANC1 cell lines.
Lenti-miR Library Screening
Cells were transduced with a lentiviral Lenti-miR library (System Biosciences)
at a low multiplicity of infection (moi < 1) such that each cell overexpressed a
single miRNA. The transduced population was then injected intrahepatically
into NOD-SCIDmice for in vivo selection of miRNAs that when overexpressed,
either promoted or suppressed metastatic liver colonization. Genomic DNA
PCR amplification and recovery of lenti-viral miRNA inserts was performed
on cells prior to injection and from liver nodules according to the manufac-
turer’s protocol. miRNA array profiling allowed for miRNA insert quantification
prior to and subsequent to in vivo selection.
Organotypic Slice Culture System
Cells to be injected were labeled with cell-tracker red or green (Invitrogen) and
inoculated into the livers of NOD-SCID or NOD-SCID gamma mice through in-
trasplenic injection. The livers were then extracted and cut into 150 mm slices
using aMcIlwain tissue chopper (Ted Pella) and plated onto organotypic tissue
culture inserts (Millipore) and cultured in William’s E Medium supplemented
with Hepatocyte Maintenance Supplement Pack (Invitrogen). After indicated
time periods, the liver slices were fixed in paraformaldehyde and imaged.
Extended protocol can be found in the Extended Experimental Procedures.
Adeno-Associated Viral Therapy
miR-483-5p and miR-551a were cloned as a polycistron consisting of both
miRNA precursor with flanking genomic sequences in tandem into the BglII
and NotI site of scAAV.GFP (Plasmid 21893, Addgene). Adeno-associated vi-
rus was packaged, purified and titered by Vector Biolabs. One day after mice
were inoculated with colorectal cancer cells, 13 1012 AAV viral particles were
injected into each mouse through intravenous injection.
Cyclocreatine Treatment of Mice
One day after inoculation of colon cancer cells, mice were injected with 10 mg
of cyclocreatine in 300 ml PBS. Treatment was continued daily for 2 weeks until
the mice were euthanized.
shRNA and Primer Sequences
shRNA, primers, and cloning sequences are listed in Tables S4, S5, and S6.
Additional experimental procedures can be found in the Extended Experi-
mental Procedures.
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TheGene Expression Omnibus (GEO) accession number for themiRNA screen
experiments reported in this paper is GSE56320.
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